Bioequivalency Study of CM082 Tablet in Healthy Volunteers
The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers.
Advanced Malignant Solid Tumors
DRUG: CM082 tablet (test product)|DRUG: CM082 tablet (reference product)
Peak plasma concentration(Cmax) of CM082 (test product or reference product) under fasted state or after meal, The Cmax ofCM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose, pre-dose(30minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,16,24,36,48,72 hour]|Area under the plasma concentration versus time curve(AUC) of CM082 (test product or reference product) under fasted state or after meal, The AUC of CM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose, pre-dose(30minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,16,24,36,48,72 hour]|Time of maximum concentration (Tmax) of CM082 (test product or reference product) under fasted state or after meal, The Tmax of CM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose, pre-dose(30minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,16,24,36,48,72 hour]
Percentage of adverse events, Percentage of adverse events as assessed by CTCAE v4.03, From the first occurrence of adverse events after administration to the cessation of adverse events, assessed up to 2 months
The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers under fasted state or after meal. In addition, the safety of single dose administration of CM082 tablet in Chinese healthy volunteers will also be evaluated.